Idioma:

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Miles, David ; Baselga, José ; Amadori, Dino ; Sunpaweravong, Patrapim ; Semiglazov, Vladimir ; Knott, Adam ; Clark, Emma ; Ross, Graham ; Swain, Sandra M.

Breast cancer research and treatment, 2013-11, Vol.142 (1), p.89-99 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
Autor: Miles, David ; Baselga, José ; Amadori, Dino ; Sunpaweravong, Patrapim ; Semiglazov, Vladimir ; Knott, Adam ; Clark, Emma ; Ross, Graham ; Swain, Sandra M.
Assuntos: Adult ; Age Factors ; Aged ; Aged patients ; Aged, 80 and over ; Analysis ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer ; Cancer patients ; Cancer research ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical Trial ; Clinical trials ; Drug therapy ; Epidermal growth factor ; Female ; Humans ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neoplasm Metastasis ; Older people ; Oncology ; Product development ; Receptor, ErbB-2 - metabolism ; Taxoids - administration & dosage ; Trastuzumab ; Treatment Outcome
É parte de: Breast cancer research and treatment, 2013-11, Vol.142 (1), p.89-99
Descrição: Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (<65 vs ≥65 years) from a randomized, double-blind, placebo-controlled phase III trial in patients with HER2-positive metastatic breast cancer. Patients who had not received previous chemotherapy or biological therapy for HER2-positive locally recurrent, unresectable or metastatic breast cancer were randomly assigned to treatment with placebo, trastuzumab, and docetaxel or with pertuzumab, trastuzumab, and docetaxel. Primary endpoint was independently assessed progression-free survival. We performed pre-specified subgroup analyses of progression-free survival according to age. The study is registered with ClinicalTrials.gov, NCT00567190. 808 patients were enrolled. Of those, 127 patients were 65 years of age or older (placebo arm: 67, pertuzumab arm: 60). Patients in both age groups experienced progression-free survival benefit with treatment in the pertuzumab arm (<65 years: HR: 0.65; 95 % CI 0.53–0.80; ≥65 years: HR: 0.52; 95 % CI 0.31–0.86). Diarrhoea, fatigue, asthenia, decreased appetite, vomiting, and dysgeusia were reported more frequently in patients 65 years of age or older compared with younger patients. Neutropenia and febrile neutropenia were reported less frequently in the older age group. The efficacy and safety data reported in CLEOPATRA suggest that the combined use of pertuzumab, trastuzumab, and docetaxel should not be limited by patient age.
Editor: Boston: Springer US
Idioma: Inglês;Russo

Links

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

Miles, David ; Baselga, José ; Amadori, Dino ; Sunpaweravong, Patrapim ; Semiglazov, Vladimir ; Knott, Adam ; Clark, Emma ; Ross, Graham ; Swain, Sandra M.

Boston: Springer US

Buscando em bases de dados remotas. Favor aguardar.